When is testing for glucose‑6‑phosphate dehydrogenase (G6PD) deficiency indicated?

G6PD Testing Indications

Test for G6PD deficiency before initiating primaquine or tafenoquine for radical cure of P. vivax or P. ovale malaria, and consider testing in high-risk ethnic populations (African American, Asian, Mediterranean descent) before exposure to oxidative stressors including certain antimalarials. 1

Primary Indications for G6PD Testing

Malaria Treatment Context (Strongest Indication)

• Mandatory testing before primaquine or tafenoquine: These drugs target hepatic hypnozoites but cause severe hemolysis in G6PD-deficient patients 1
• Quantitative G6PD testing required for tafenoquine: Do not use if activity <70% 1
• Primaquine dosing adjustments:
  • Intermediate deficiency (30-70%) with non-Mediterranean variant (A-): Use weekly primaquine (0.75 mg base/kg, maximum 45 mg) for 8 weeks with close hemolysis monitoring 1
  • Mediterranean variant (B-): Very high risk of severe hemolysis; avoid primaquine even with extended dosing regimens 1

High-Risk Populations Warranting Screening

Based on prevalence data, testing is clinically warranted for:

• African American males (12.2% deficiency rate) and females (4.1%) 2
• Asian males (4.3%, with most severe class II variants) 2
• Hispanic males 2
• Mediterranean descent individuals 1
• Military personnel before deployment to malarious regions 2

Secondary Clinical Scenarios

Neonatal Jaundice

• Test jaundiced newborns receiving phototherapy whose family history, ethnicity, or geographic origin suggests risk 3
• Test when response to phototherapy is poor 3
• Critical caveat: Standard semiquantitative screening methods miss most heterozygous females (partially deficient), who represent a significant at-risk population 4

Unexplained Hemolytic Anemia

• Consider testing when hemolysis occurs after:
  • Drug exposure (antimalarials, sulfonamides, other oxidative drugs)
  • Infections
  • Diabetic ketoacidosis (hemolysis can occur during correction of hyperglycemia in newly diagnosed diabetes) 5
• Nonimmune hydrops fetalis or severe fetal anemia: Consider G6PD testing if standard workup is negative, particularly with parental history suggesting deficiency 6

Testing Method Considerations

Quantitative vs. Qualitative Testing

• Quantitative testing preferred when available, especially for:
  • Tafenoquine eligibility (requires >70% activity) 1
  • Heterozygous females (qualitative methods miss partial deficiency) 4
  • Patients with concurrent hematological conditions 7

Timing Pitfalls

• Avoid testing during acute hemolysis: Reticulocytes have higher G6PD activity, causing false-negative results
• Retest 2-3 months after hemolytic episode if initial test is normal but clinical suspicion remains high
• Flow cytometry can quantify percentage of G6PD-deficient RBCs, particularly useful in heterozygous females 7

Common Clinical Pitfalls

1. Assuming normal screening excludes deficiency in females: Heterozygous females with X-chromosome inactivation patterns may have normal enzyme activity on standard tests but still have significant populations of deficient RBCs 4, 7

2. Testing only symptomatic patients: Most G6PD-deficient individuals (5.5% of neonates in endemic areas) remain undiagnosed until exposed to oxidative stress 8

3. Using inappropriate cutoffs: Semiquantitative methods using 2.1 U/g Hb cutoff miss partial deficiency; quantitative methods should use 6.4 U/g Hb cutoff 4

4. Overlooking sickle cell disease interference: Flow cytometry shows false negatives in patients with sickle cell disease 7